ABC & SCAI: Advancing Health Equity in Secondary ASCVD and Lp(a) Management-Secondary ASCVD Management: Are We Making Progress? Dr. Tayo Addo

Secondary ASCVD Management: Are We Making Progress? Dr. Tayo Addo

Video Transcription

Video Summary

Decades of research confirm cholesterol's link to heart disease, especially prevalent in Western societies. Statin trials over thirty years show consistent reductions in cardiovascular events, making statins vital for secondary prevention. High-potency statins like atorvastatin and rosuvastatin significantly lower LDL levels, correlating with reduced risk of heart events. The 2023 U.S. guidelines advocate high-intensity statins for most patients with atherosclerotic disease. However, LDL management in the U.S. is inadequate, with many patients having uncontrolled LDL levels. Enhancing statin adherence and integrating non-statin therapies, like PCSK9 monoclonal antibodies, can improve outcomes.

Keywords

cholesterol

statins

LDL

cardiovascular

PCSK9